Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
UBS
McKesson
Fuji
Johnson and Johnson
Teva
Merck
Boehringer Ingelheim
US Department of Justice

Generated: August 18, 2018

DrugPatentWatch Database Preview

Rhodes Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for RHODES PHARMS, and when can generic versions of RHODES PHARMS drugs launch?

RHODES PHARMS has seventeen approved drugs.

There are eight US patents protecting RHODES PHARMS drugs.

There are forty-four patent family members on RHODES PHARMS drugs in fifteen countries and one supplementary protection certificate in one country.

Summary for Rhodes Pharms
International Patents:44
US Patents:8
Tradenames:11
Ingredients:10
NDAs:17

Drugs and US Patents for Rhodes Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rhodes Pharms HYDROCODONE BITARTRATE AND ACETAMINOPHEN acetaminophen; hydrocodone bitartrate TABLET;ORAL 202991-002 Apr 12, 2016 AA RX No No ➤ Sign Up ➤ Sign Up
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-004 Apr 17, 2015 RX Yes No 7,438,930 ➤ Sign Up Y Y ➤ Sign Up
Rhodes Pharms FENOFIBRATE (MICRONIZED) fenofibrate CAPSULE;ORAL 075753-001 Sep 3, 2002 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for RHODES PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 2015-12-23
➤ Subscribe Extended-release Capsules 15 mg, 20 mg, 40 mg and 50 mg ➤ Subscribe 2015-12-28
➤ Subscribe Oral Solution 5 mg/5mL ➤ Subscribe 2011-02-25
➤ Subscribe Tablets 2 mg, 4 mg, and 8 mg ➤ Subscribe 2013-08-05
➤ Subscribe Extended-release Capsules 10 mg ➤ Subscribe 2015-12-24
➤ Subscribe Extended-release Capsules 30 mg ➤ Subscribe 2016-03-28
➤ Subscribe Injection 2 mg/mL ➤ Subscribe 2011-06-22

Non-Orange Book US Patents for Rhodes Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis ➤ Sign Up
6,673,367 Controlled/modified release oral methylphenidate formulations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Rhodes Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292 Luxembourg ➤ Sign Up PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Argus Health
Moodys
Fuji
Accenture
Cipla
Cantor Fitzgerald
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.